Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets

Vaccine

Volumn 34, Issue 4, 2016, Pages 466-473

  Music, Nedzad ^a,b   Reber, Adrian J ^a   Kim, Min Chul ^c,d   York, Ian A ^a   Kang, Sang Moo ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

^d Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

Author keywords

Cross protection; Ferret; M2e protein

Indexed keywords

INFLUENZA VACCINE; PROTEIN M2; SPLIT VACCINE; UNCLASSIFIED DRUG; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; FERRET; IMMUNOGENICITY; INFLAMMATION; INFLUENZA A (H1N1); INFLUENZA A VIRUS (H1N1); LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; TANDEM REPEAT; TREATMENT RESPONSE; VIRUS LIKE AGENT; VIRUS STRAIN; WEIGHT REDUCTION; ANIMAL; ANTIBODY PRODUCTION; BLOOD; IMMUNOLOGY; MALE; MUSTELA PUTORIUS FURO; ORTHOMYXOVIRIDAE INFECTIONS; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CROSS PROTECTION; FERRETS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; ORTHOMYXOVIRIDAE INFECTIONS; T-LYMPHOCYTE SUBSETS; VACCINES, VIRUS-LIKE PARTICLE; VIRAL MATRIX PROTEINS;

EID: 84952976578     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.12.023     Document Type: Article

References (24)

1. Clark N.M., Lynch J.P. Influenza: epidemiology, clinical features, therapy, and prevention. Semin Respir Crit Care Med 2011, 32(Aug. (4)):373-392.
2. Nair H., Brooks W.A., Katz M., Roca A., Berkley J.A., Madhi S.A., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011, 378(Dec. (9807)):1917-1930.
3. WHO World Health Organization Fact Sheet No. 211. Influenza (Seasonal) 2009, http://www.who.int/mediacentre/factsheets/fs211/en/index.html.
4. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(Nov (20)):1945-1952.
5. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325(Jul. (5937)):197-201.
6. Ito T., Gorman O.T., Kawaoka Y., Bean W.J., Webster R.G. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol 1991, 65(10):5491-5498.
7. Zebedee S.L., Lamb R.A. Nucleotide sequences of influenza A virus RNA segment 7: a comparison of five isolates. Nucl Acids Res 1989, 17(Apr. (7)):2870.
8. Du L., Zhou Y., Jiang S. Research and development of universal influenza vaccines. Microbes Infect/Inst Pasteur 2010, 12(4):280-286.
9. Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A universal human influenza A vaccine. Virus Res 2004, 103(Jul. (1-2)):173-176.
10. Kang S.M., Kim M.C., Compans R.W. Virus-like particles as universal influenza vaccines. Expert Rev Vaccines 2012, 11(8):995-1007.
11. Zhao G., Lin Y., Du L., Guan J., Sun S., Sui H., et al. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 2010, 7:9.
12. Kang S.M., Song J.M., Compans R.W. Novel vaccines against influenza viruses. Virus Res 2011, 162(Dec. (1-2)):31-38.
13. Song J.M., Wang B.Z., Park K.M., Van Rooijen N., Quan F.S., Kim M.C., et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS ONE 2011, 6(1):e14538.
14. Kim M.C., Song J.M., O Eunju, Kwon Y.M., Lee Y.J., Compans R.W., et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Molecular therapy. J Am Soc Gene Ther 2013, 21(2):485-492.
15. Banner D., Kelvin A.A. The current state of H5N1 vaccines and the use of the ferret model for influenza therapeutic and prophylactic development. J Infect Dev Countries 2012, 6(6):465-469.
16. Belser J.A., Katz J.M., Tumpey T.M. The ferret as a model organism to study influenza A virus infection. Dis Models Mech 2011, 4(Sep. (5)):575-579.
17. Maher J.A., DeStefano J. The ferret: an animal model to study influenza virus. Lab Anim 2004, 33(Oct (9)):50-53.
18. Reuman P.D., Keely S., Schiff G.M. Assessment of signs of influenza illness in the ferret model. J Virol Methods 1989, 24(Apr-May (1-2)):27-34.
19. Music N., Reber A.J., Lipatov A.S., Kamal R.P., Blanchfield K., Wilson J.R., et al. Influenza vaccination accelerates recovery of ferrets from lymphopenia. PLoS ONE 2014, 9(6):e100926.
20. Reed L., Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
21. WHO Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza 2011, WHO Press, World Health Organization, Switzerland.
22. Matsuoka Y., Lamirande E.W., Subbarao K. The ferret model for influenza. Current Protocols in Microbiology 2009 May, John Wiley & Sons, Inc., 15G.2.1-15G.2.29, Published online May 2009 in Wiley Interscience (www.interscience.wiley.com). 10.1002/9780471729259.mc15g02s13.
23. Kim M.C., Lee Y.N., Ko E.J., Lee J.S., Kwon Y.M., Hwang H.S., et al. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection. Molecular therapy. J Am Soc Gene Ther 2014, 22(7):1364-1374.
24. Shin J.S., Do Hwang S., Kim H.S., Cho S.W., Seo S.H. Protection of ferrets from infection by swine-origin 2009 A (H1N1) influenza virus by the inactivated vaccine. Viral Immunol 2010, 23(Aug. (4)):395-402.